Prednisone
- Generic Name
- Prednisone
- Brand Names
- Deltasone, Rayos, Winpred
- Drug Type
- Small Molecule
- Chemical Formula
- C21H26O5
- CAS Number
- 53-03-2
- Unique Ingredient Identifier
- VB0R961HZT
- Background
A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.
Prednisone was granted FDA approval on 21 February 1955.
- Indication
Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.
- Associated Conditions
- Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis
- Associated Therapies
- Palliative Treatment
Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 102
- Registration Number
- NCT03436654
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Northwestern University, Evanston, Illinois, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side Effects
- First Posted Date
- 2018-02-07
- Last Posted Date
- 2019-08-15
- Lead Sponsor
- Holy Name Medical Center, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT03424733
- Locations
- 🇺🇸
Holy Name Medical Center, Teaneck, New Jersey, United States
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
- Conditions
- Interventions
- First Posted Date
- 2018-02-01
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- ECOG-ACRIN Cancer Research Group
- Target Recruit Count
- 223
- Registration Number
- NCT03419234
- Locations
- 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸Richard L. Roudebush Veterans Affairs Medical Center, Indianapolis, Indiana, United States
🇺🇸Sidney and Lois Eskenazi Hospital, Indianapolis, Indiana, United States
Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-01-29
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Cardiff Oncology
- Target Recruit Count
- 72
- Registration Number
- NCT03414034
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
- Conditions
- Interventions
- First Posted Date
- 2018-01-26
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 265
- Registration Number
- NCT03412565
- Locations
- 🇺🇸
Cancer Center of Central Connecticut - Southington, Southington, Connecticut, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Avera Medical Group - Oncology & Hematology, Sioux Falls, South Dakota, United States
Belatacept Pilot Study in Lung Transplantation Immunosuppression in Lung Transplantation
- First Posted Date
- 2018-01-02
- Last Posted Date
- 2022-11-25
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 27
- Registration Number
- NCT03388008
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Houston Methodist Hospital, Houston, Texas, United States
A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- First Posted Date
- 2017-12-27
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 47
- Registration Number
- NCT03384654
- Locations
- 🇺🇸
Children'S Healthcare Of Atlanta/Emory Univ. Dept. Of Pediatrics, Atlanta, Georgia, United States
🇺🇸Newark Beth Israel Medical Center, Newark, New Jersey, United States
🇺🇸UT Southwestern Medical Center, Dallas, Texas, United States
Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-12-04
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 7
- Registration Number
- NCT03360721
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
CABAzitaxel With or Without Prednisone in Patients With Metastatic CAstration REsistant Prostate Cancer Progressed During or After a Previous Docetaxel-based Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2017-11-29
- Last Posted Date
- 2017-12-14
- Lead Sponsor
- Consorzio Oncotech
- Target Recruit Count
- 220
- Registration Number
- NCT03356912
- Locations
- 🇮🇹
University Federico II of Naples, Naples, Italy
An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-11-09
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 292
- Registration Number
- NCT03338790
- Locations
- 🇺🇸
Local Institution - 0037, Miami, Florida, United States
🇺🇸Local Institution - 0009, Marietta, Georgia, United States
🇺🇸Local Institution - 0012, Detroit, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.